HIV New Product Introduction Toolkit

In mid-2021, national HIV programmes began to transition treatment for children living with HIV to dolutegravir (DTG) 10 ...

CHAI developed these frequently asked questions (FAQs) to lay out information for communities and PLHIV on the subject of DRV/r (400/50...

Darunavir (DRV) is a best-in-class protease inhibitor (PI) used in combination with other antiretroviral (ARV) drugs for the...

A presentation with the latest information on DRV/r (400/50mg) and considerations for adult second line treatment optimization.

CHAI developed these frequently asked questions (FAQs) to lay out information for national HIV programs considering the adoption and...

Regional HIV Market Briefs, produced by the CHAI HIV Access Program, provide the latest region-specific market intelligence on ART...

CHAI is pleased to release the 12th issue of our annual HIV market report. This report provides a detailed look at the complex,...

This product profile provides a clinical overview of pediatric DTG, market updates and implementation considerations, and provides...

This document is meant to assist national HIV programs in pDTG adoption. This document provides a summary of pDTG, including advantages...

CHAI has developed this memo to lay out information for national HIV programs considering the introduction of pediatric...

Low- and middle-income countries (LMIC) currently experience low testing coverage in the face of increasing demand to meet the needs of...

HIV i-Base is a treatment activist group based in London, UK. The organization is committed to providing timely and up to date...

Fillable report and presentation template for governments to adjust as needed for introduction of pediatric DTG. English | French

A compilation of recently published WHO guidelines, including CHAI briefs on these guidelines. 2021 WHO Consolidated Guidelines on HIV...

Introducing the fifth edition of CHAI’s HIV Mid-Year Market Memo, a brief that covers the latest trends in the HIV space in low- and...

This policy brief outlines key considerations to facilitate effective transition to more clinically appropriate regimens as optimal...

These consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring bring together existing and new...

In March 2021, the WHO published new clinical and service delivery recommendations for HIV prevention, treatment, and care. In April, the...

This sixth edition of the Optimal Formulary and Limited-use List supports the transition to optimal WHO-recommended ART regimens for...

The Integration Readiness Assessment Tool is a checklist to evaluate and help select the sites in a country where tuberculosis...